In the BioHarmony Drug Report Database

"Preview" Icon

Ivosidenib

Tibsovo (ivosidenib) is a small molecule pharmaceutical. Ivosidenib was first approved as Tibsovo on 2018-07-20. It is used to treat myeloid leukemia acute in the USA. The pharmaceutical is active against isocitrate dehydrogenase [NADP] cytoplasmic. Tibsovo’s patents are valid until 2039-06-07 (FDA).

 

Trade Name

 

Tibsovo
 

Common Name

 

ivosidenib
 

ChEMBL ID

 

CHEMBL3989958
 

Indication

 

myeloid leukemia acute
 

Drug Class

 

Mutated isocitrate dehydrogenase (IDH) inhibitors

Image (chem structure or protein)

Ivosidenib structure rendering